About Serine incorporator 3
Serine incorporator 3 (SERINC3) is a protein
from Homo sapiens identified by UniProt accession
Q13530, 473 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | Serine incorporator 3 |
| UniProt accession | Q13530 |
| Gene | SERINC3 |
| Organism | Homo sapiens |
| Length | 473 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (27)
Diseases linked to this target (Open Targets).
- autosomal recessive hypophosphatemic rickets · score 0.04
- Primary hypomagnesemia with secondary hypocalcemia · score 0.03
- melorheostosis · score 0.03
- hyperostosis corticalis generalisata · score 0.03
- Autosomal dominant primary hypomagnesemia with hypocalciuria · score 0.03
- hypertension · score 0.03
- infect · score 0.02
- infection · score 0.02
- neoplasm · score 0.01
- microphthalmia with limb anomalies · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13530-F1 | alphafold | PREDICTED | 76.31 | — |
Amino-acid sequence (473 residues)
MGAVLGVFSL ASWVPCLCSG ASCLLCSCCP NSKNSTVTRL IYAFILLLST VVSYIMQRKE METYLKKIPG FCEGGFKIHE ADINADKDCD VLVGYKAVYR ISFAMAIFFF VFSLLMFKVK TSKDLRAAVH NGFWFFKIAA LIGIMVGSFY IPGGYFSSVW FVVGMIGAAL FILIQLVLLV DFAHSWNESW VNRMEEGNPR LWYAALLSFT SAFYILSIIC VGLLYTYYTK PDGCTENKFF ISINLILCVV ASIISIHPKI QEHQPRSGLL QSSLITLYTM YLTWSAMSNE PDRSCNPNLM SFITRITAPT LAPGNSTAVV PTPTPPSKSG SLLDSDNFIG LFVFVLCLLY SSIRTSTNSQ VDKLTLSGSD SVILGDTTTS GASDEEDGQP RRAVDNEKEG VQYSYSLFHL MLCLASLYIM MTLTSWYSPD AKFQSMTSKW PAVWVKISSS WVCLLLYVWT LVAPLVLTSR DFS
Explore Serine incorporator 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets